Regeneron

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Former CEO wins bidding war for 23andMe, beating Regeneron

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the genetic testing business.

News

New auction for 23andMe sought with $305m bid from ex-CEO

A new auction for bankrupt genetic testing company 23andMe looks likely after former CEO Anne Wojcicki offered to outbid Regeneron.

Oncology

Regeneron at ASCO 25: Advancing multiple myeloma treatment

News

23andMe founder isn't giving up her bid to regain control

23andMe founder Anne Wojcicki is hoping to make a fresh bid for the genetic testing firm, riding out a takeover deal with Regeneron.

News

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC

Regeneron's PD-1 inhibitor Libtayo hits the mark where MSD's Keytruda missed in a form of non-melanoma skin cancer.

Dupixent is first FDA-approved drug for rare skin disease

Former CEO wins bidding war for 23andMe, beating Regeneron

New auction for 23andMe sought with $305m bid from ex-CEO

Regeneron at ASCO 25: Advancing multiple myeloma treatment

23andMe founder isn't giving up her bid to regain control

ASCO 25: Regeneron hails Libtayo's adjuvant data in CSCC

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Regeneron

Editor's Picks